Discover investment opportunities in Top 10 Stocks Under $170 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 10 Stocks Under $170 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 10 Stocks Under $170 using our Smart AI Filter.
9 stocks found for "Top 10 Stocks Under $170"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.54 Risk measure | ±32.2% Price volatility | 27.1 Valuation | 0.46% Annual yield | |||
0.76 Risk measure | ±35.0% Price volatility | 13.3 Valuation | 2.24% Annual yield | |||
0.22 Risk measure | ±27.3% Price volatility | 15.0 Valuation | 2.83% Annual yield | |||
1.37 Risk measure | ±41.7% Price volatility | 12.3 Valuation | 0.45% Annual yield | |||
1.27 Risk measure | ±48.5% Price volatility | 13.5 Valuation | 0.00% Annual yield | |||
0.45 Risk measure | ±34.4% Price volatility | 36.3 Valuation | 0.00% Annual yield | |||
1.02 Risk measure | ±54.4% Price volatility | 38.7 Valuation | 0.03% Annual yield | |||
0.83 Risk measure | ±32.5% Price volatility | 20.0 Valuation | 0.47% Annual yield | |||
0.51 Risk measure | ±26.4% Price volatility | 38.2 Valuation | 0.81% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors contribute to NVIDIA's (NVDA) stock appeal?
A: NVIDIA is known for its leadership in graphics processing units (GPUs) which are vital for gaming, AI, and data centers. Its consistent R&D investments and industry partnerships bolster long-term growth potential. However, volatility in the semiconductor market and supply chain issues can impact performance.
Q: How does Google's parent company, Alphabet (GOOGL), generate its revenue?
A: Alphabet primarily earns through Google Ads, which constitutes the majority of its revenue. Additional streams include Google Cloud, YouTube, and hardware products. Market dominance in digital advertising and search engines strengthens its competitive positioning.
Q: What differentiates Amazon (AMZN) from other retail stocks?
A: Amazon's integration of e-commerce, AWS cloud services, and logistics provides revenue diversity, aiding resilience against retail volatility. Its Prime membership model fosters customer loyalty and recurring income, supporting competitive advantages in the e-commerce space.
Q: What growth prospects does Apple (AAPL) offer investors?
A: Apple's robust ecosystem, including iPhones, Macbooks, services, and accessories, drives sustained revenue growth. The company's innovation in technology and transition toward services, including Apple Music and TV+, offers additional revenue opportunities.
Q: Why might Microsoft (MSFT) appeal to tech investors?
A: Microsoft's diverse product suite, encompassing software, cloud services (Azure), and gaming, provides diversified revenue streams. Its dominance in enterprise solutions and AI advancements positions it well for continued growth in various technology sectors.
Q: What attracts investors to Gilead Sciences (GILD) in the biopharma sector?
A: Gilead Sciences benefits from a strong pipeline in antiviral drugs, especially treatments for HIV and liver disease. Its proven track record in drug development and strategic acquisitions supports future growth, notwithstanding the inherent risks in pharmaceutical R&D.